Shanghai, China—D3 Bio (Wuxi) Co. Ltd (“D3 Bio” or “Company”), a biotechnology company that focuses on discovery, development, and registration of innovative medicines in the fields of oncology and immune-oncology, announced the company’s new research data of its oncology program D3L-001 to be presented at the Society for Immunotherapy of Cancer 2022 (SITC2022) in Boston, USA. Those data highlight D3 Bio’s pipeline innovations in cancer treatment.
Title: Preclinical Characterization of D3L-001, a novel bispecific antibody that enhances phagocytosis and eradication of HER2 positive (HER2+) solid tumor via HER2 and CD47 dual blockade
The full article will be available in a Journal for ImmunoTherapy of Cancer (JITC) supplement, which will be published on Nov. 7 at 8 a.m. EST.
D3L-001 is a novel HER2×CD47 bi-specific antibody (bsAb), which demonstrated potent and synergistic anti-tumor effect via HER2 guided CD47 co-blocking in both in vitro and in vivo models. D3L-001 is in IND enabling stage and will be developed as a new therapy for Her2 positive cancers.
D3 Bio is a globally orientated, clinical stage biotechnology company that focuses on the discovery, development and registration of new medicines in oncology and immunology. At D3 Bio, we fully leverage our clinical insight and biomarker strategy to guide our discovery effort and compound development, aiming to create novel and clinically meaningful new therapies for patients in need.
D3 Bio is funded by globally renowned investors, including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.
For inquiries, please contact: